These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 25146720)

  • 41. What is the optimal initial management of the older MCL patient?
    Kluin-Nelemans JC; Doorduijn JK
    Best Pract Res Clin Haematol; 2018 Mar; 31(1):99-104. PubMed ID: 29452672
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Clinical comparison of CHO regimen versus CHOP regimen for treatment of patients with intermediate-grade non-Hodgkin's lymphoma].
    Yuan ZY; Xu RH; He YJ; Guan ZZ
    Ai Zheng; 2003 Apr; 22(4):393-6. PubMed ID: 12703996
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma.
    Micallef IN; Kahl BS; Maurer MJ; Dogan A; Ansell SM; Colgan JP; Geyer S; Inwards DJ; White WL; Habermann TM
    Cancer; 2006 Dec; 107(12):2826-32. PubMed ID: 17099879
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.
    Romaguera JE; Wang M; Feng L; Fayad LE; Hagemeister F; McLaughlin P; Rodriguez MA; Fanale M; Orlowski R; Kwak LW; Neelapu S; Oki Y; Pro B; Younes A; Samaniego F; Fowler N; Hartig K; Valentinetti M; Smith J; Ford P; Naig A; Medeiros LJ; Kantarjian HM; Goy A
    Cancer; 2018 Jun; 124(12):2561-2569. PubMed ID: 29723393
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma.
    White D; Kassim A; Bhaskar B; Yi J; Wamstad K; Paton VE
    Cancer; 2013 Jan; 119(2):339-47. PubMed ID: 22811009
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Ten years progression-free survival obtained in a patient with mantle cell lymphoma].
    Wysokińska E; Kolak A; Starosławska E; Kieszko D; Kamińska M; Surdyka D; Mocarska A; Burdan F
    Pol Merkur Lekarski; 2015 May; 38(227):280-2. PubMed ID: 26039024
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
    Wang M; Fayad L; Cabanillas F; Hagemeister F; McLaughlin P; Rodriguez MA; Kwak LW; Zhou Y; Kantarjian H; Romaguera J
    Cancer; 2008 Nov; 113(10):2734-41. PubMed ID: 18973182
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma.
    Lee J; Suh C; Kang HJ; Ryoo BY; Huh J; Ko YH; Eom HS; Kim K; Park K; Kim WS
    Ann Oncol; 2008 Dec; 19(12):2079-83. PubMed ID: 18689866
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma.
    Weigert O; Pastore A; Rieken M; Lang N; Hiddemann W; Dreyling M
    Leukemia; 2007 Mar; 21(3):524-8. PubMed ID: 17268531
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD.
    Mato AR; Svoboda J; Feldman T; Zielonka T; Agress H; Panush D; Miller M; Toth P; Lizotte PM; Nasta S; Goldberg S; Chong E; Schuster S; Pecora AL; Goy A
    Cancer; 2012 Jul; 118(14):3565-70. PubMed ID: 22180256
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
    Feugier P; Van Hoof A; Sebban C; Solal-Celigny P; Bouabdallah R; Fermé C; Christian B; Lepage E; Tilly H; Morschhauser F; Gaulard P; Salles G; Bosly A; Gisselbrecht C; Reyes F; Coiffier B
    J Clin Oncol; 2005 Jun; 23(18):4117-26. PubMed ID: 15867204
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
    Orlowski RZ; Nagler A; Sonneveld P; Bladé J; Hajek R; Spencer A; San Miguel J; Robak T; Dmoszynska A; Horvath N; Spicka I; Sutherland HJ; Suvorov AN; Zhuang SH; Parekh T; Xiu L; Yuan Z; Rackoff W; Harousseau JL
    J Clin Oncol; 2007 Sep; 25(25):3892-901. PubMed ID: 17679727
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bortezomib (Velcade), rituximab, cyclophosphamide, and dexamethasone combination regimen is active as front-line therapy of low-grade non-Hodgkin lymphoma.
    Nabhan C; Villines D; Dalal N; Tolzien K; Kozolff M; Starr A
    Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):26-31. PubMed ID: 21752745
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma.
    Lee HJ; Romaguera JE; Feng L; Desai AP; Zhang L; Fanale M; Samaniego F; Hagemeister FB; Fayad LE; Rodriguez MA; Medeiros JL; Hartig K; Nomie K; Ahmed M; Badillo M; Ye H; Oki Y; Lin P; Nastoupil L; Westin J; Wang M
    Oncologist; 2017 May; 22(5):549-553. PubMed ID: 28408615
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma.
    Beaven AW; Shea TC; Moore DT; Feldman T; Ivanova A; Ferraro M; Ford P; Smith J; Goy A
    Leuk Lymphoma; 2012 Feb; 53(2):254-8. PubMed ID: 21812533
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA).
    Bachy E; Camus V; Thieblemont C; Sibon D; Casasnovas RO; Ysebaert L; Damaj G; Guidez S; Pica GM; Kim WS; Lim ST; André M; García-Sancho AM; Penarrubia MJ; Staber PB; Trotman J; Hüttmann A; Stefoni V; Re A; Gaulard P; Delfau-Larue MH; de Leval L; Meignan M; Li J; Morschhauser F; Delarue R
    J Clin Oncol; 2022 Jan; 40(3):242-251. PubMed ID: 34843406
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The clinical features, therapeutic responses, and prognosis of the patients with mantle cell lymphoma.
    Ying ZT; Zheng W; Wang XP; Xie Y; Tu MF; Lin NJ; Ping LY; Liu WP; Deng LJ; Zhang C; Zhu J; Song YQ
    Chin J Cancer; 2012 Jul; 31(7):348-53. PubMed ID: 22704490
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP.
    Thomas DW; Owen RG; Johnson SA; Hillmen P; Seymour JF; Wolf MM; Rule SA
    Leuk Lymphoma; 2005 Apr; 46(4):549-52. PubMed ID: 16019483
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma.
    Castillo JJ; Reagan JL; Sikov WM; Winer ES
    Br J Haematol; 2015 May; 169(3):352-5. PubMed ID: 25612847
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma.
    Sonbol MB; Hilal T; Dueck AC; Rosenthal AC; Conley CR; Kosiorek HE; Ginos BF; Gano KM; Nichols CS; Leis JF; Johnston PB; Habermann TM; Northfelt DW; Bergsagel PL; Inwards DJ; Witzig TE; Ansell SM; Reeder CB
    Leuk Lymphoma; 2018 Sep; 59(9):2128-2134. PubMed ID: 29320913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.